

February 28th, 2014

Governor Mike Pence 200 West Washington Street, Room 200 Indianapolis, IN 46204

Dear Governor Pence:

As the President and CEO of RetireSafe I am writing to request that you sign SB 262 on the substitution of biosimilar products into law.

RetireSafe is a 400,000 strong nationwide advocacy organization who is working to ensure that patient safety is at the forefront of the biosimilars policy discussion. We believe that when interchangeable biosimilar products are substituted, communication among patients, pharmacists, and health care providers is essential to patient care and therefore, we fully support SB 262 and are concerned that patient safety will be compromised if this legislation is not enacted.

Others have weighed in on why biosimilars are unique and the science behind this groundbreaking medicine. Because the medicine and its structure are complicated, from the perspective of the nearly 8,400 RetireSafe supporters in Indiana, it seems such a common sense requirement that the patient's physician be notified if a biosimilar is substituted by the pharmacist. Procedural inconvenience should not stand in the way of patient safety.

We appreciate your concern with patient safety and your efforts to make it a priority in Indiana. We have supported the FDA in its mission to safely bring biosimilars to the U.S. and we support your efforts with SB 262.

Thair Phillips
President/CEO

in Phillips

RetireSafe